Treatment options in candidaemia
Related Experiment Video
Updated: Jul 16, 2026

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
Published on: September 16, 2022
Meinolf Karthaus1, Oliver A Cornely
1Department Hematology/Oncology and Palliative Care, Ev. Krankenhaus Bielefeld, Med. Klinik im Johannesstift, Schildescher Strasse, Bielefeld. Meinolf.Karthaus@vkb.de
Abstract:
Candida spp. are the fourth leading cause of bloodstream infections. Mortality in candidaemia remains substantial. In recent years Candida non-albicans species are increasing. Inadequate and delayed antifungal treatment for candidaemia is associated with increased hospital mortality. While fluconazole has been shown to be safe and effective in Candida albicans, amphotericin B deoxycholate has substantial adverse events although being effective in most patients with candidaemia caused by non-albicans species. With the advent of new antifungals the efficacy and safety of antifungal treatment have been improved substantially. This review summarises the new treatment options in candidaemia.
Related Concept Videos
Cryptococcal Meningitis
Candidiasis
Antifungal Agents
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Fungal Phylum Microsporidia
Endocarditis III: Medical Management
